| Literature DB >> 35054925 |
Alexandra Prodea1,2, Alexandra Mioc2,3, Christian Banciu4, Cristina Trandafirescu1,2, Andreea Milan1,2, Roxana Racoviceanu1,2, Roxana Ghiulai1,2, Marius Mioc1,2, Codruta Soica1,2.
Abstract
Triterpenic compounds stand as a widely investigated class of natural compounds due to their remarkable therapeutic potential. However, their use is currently being hampered by their low solubility and, subsequently, bioavailability. In order to overcome this drawback and increase the therapeutic use of triterpenes, cyclodextrins have been introduced as water solubility enhancers; cyclodextrins are starch derivatives that possess hydrophobic internal cavities that can incorporate lipophilic molecules and exterior surfaces that can be subjected to various derivatizations in order to improve their biological behavior. This review aims to summarize the most recent achievements in terms of triterpene:cyclodextrin inclusion complexes and bioconjugates, emphasizing their practical applications including the development of new isolation and bioproduction protocols, the elucidation of their underlying mechanism of action, the optimization of triterpenes' therapeutic effects and the development of new topical formulations.Entities:
Keywords: cyclodextrins; cytotoxicity; inclusion complexes; phytocompounds; triterpenes
Mesh:
Substances:
Year: 2022 PMID: 35054925 PMCID: PMC8775686 DOI: 10.3390/ijms23020736
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Biological activities of triterpenic compounds.
| Number | Chemical Structure | Triterpenic Compound | Biological Effects | References |
|---|---|---|---|---|
| 1 |
| Lupeol | anticancer, antihyperglycemic, antidyslipidemic, anti-inflammatory, antioxidant, antimicrobial | [ |
| 2 |
| Betulin (Bet, 3-lup-20(29)-ene-3β,28-diol) | anti-inflammatory, antimicrobial, antifibrotic, antiproliferative, wound-healing properties | [ |
| 3 |
| betulin 3,28-diphthalate (DPhB) | no data available | [ |
| 4 |
| betulin 3,28-disuccinate (DScB) | no data available | [ |
| 5 |
| betulin 3,28-disulfate (DSB) | no data available | [ |
| 6 |
| betulin 3-acetate-28-sulfate (ASB) | no data available | |
| 7 |
| Betulinic acid (BA, 3β-hydroxy-lup-20(29)-en-28-oic acid) | antiviral, antihyperglycemic, anti-inflammatory, antioxidant, anticancer | [ |
| 8 |
| Betulonic acid (BoA, lup-20(29)-en-3-oxo-28-oic) | anticancer, antiviral, antimicrobial | [ |
| 9 |
| Oleanolic acid (OA, 3β-hydroxyolean-12-en-28-oic acid) | antioxidant, anticancer, antidiabetic, antihypertensive, hepatoprotective, antimicrobial, antiparasitic | [ |
| 10 |
| Maslinic acid (MA, (2α,3β)-2,3-dihydroxyolean-12-en-28-oic acid) | antioxidant, antitumor, neuroprotective, antidiabetic, cardioprotective, antiparasitic | [ |
| 11 |
| Echinoscystic acid (EA, 3,16-dihydroxyolean-12-en-28-oic acid) | analgesic, anti-inflammatory, neuroprotective, antiosteoporotic | [ |
| 12 |
| Taraxasterol ((3β,18α,19α)-Urs-20(30)-en-3-ol) | anticancer, anti-inflammatory, antimicrobial, effective against snake venom | [ |
| 13 |
| Taraxerol (3β-Taraxerol) | ||
| 14 |
| Glycyrrhetinic acid (GA, 3beta-Hydroxy-11-oxoolean-12-en-30-oic acid) | anti-inflammatory, anticancer | [ |
| 15 |
| Ursolic acid (UA, 3 β-hydroxy-urs-12-en-28-oic acid) | anticancer, antihypertensive, reduces kidney damage, anti-HIV, antihepatitic, antimalarial, antibacterial | [ |
| 16 |
| Corosolic acid (CA, (2α,3β)-2,3-Dihydroxyurs-12-en-28-oic acid) | antihyperglycemic, anticancer | [ |
| 17 |
| Asiatic acid ((2α,3β)-2,3,23-Trihydroxyurs-12-en-28-oic acid) | anticancer, neuroprotective, antihypertension, anti-atherosclerotic and wound-healing properties | [ |
| 18 |
| Madecassic acid ((2α,3β,6β)-2,3,6,23-Tetrahydroxyurs-12-en-28-oic acid) | anti-ischemic in retinopathies | [ |
| 19 |
| Ilexgenin A ((3β)-3,19-Dihydroxyurs-12-ene-24,28-dioic acid) | anti-atherosclerotic, anti-inflammatory, anticancer | [ |
| 20 |
| α-Amirin | analgesic, anticonvulsant, anticholytic, antidepressive, anti-inflammatory, antihyperglycemic, gastroprotective, hepatoprotective, hypolipidemic | [ |
| 21 |
| β-Amirin | analgesic, anticonvulsant, anticholytic, antidepressive, anti-inflammatory, antihyperglycemic, gastroprotective, hepatoprotective, hypolipidemic | |
| 22 |
| Cycloartenol ((3β,9β)-9,19-Cyclolanost-24-en-3-ol) | anti-inflammatory, anticancer, antioxidant, antimicrobial | [ |
| 23 |
| GAN-HLDOA (ganoderic acid 3-hydroxy-lanosta-8,24-dien-26-oic acid) | anticancer | [ |
Figure 1The chemical structure of several triterpenic saponins: Asiaticoside (24), Madecassoside (25), Pedunculoside (26), Azukisaponin V (27), Momordicoside K (28), Momordicoside L (29), Soyasaponin I (30), Saikosaponin-D (31), Bersimoside I (32), Bersimoside II (33) and Glycyrrhizic acid (34).
Figure 2Structures of native cyclodextrins.
Physicochemical and toxicological properties of CDs.
| Characteristic | Type of Native Cyclodextrins | Type of Semisynthetic Cyclodextrins | ||||
|---|---|---|---|---|---|---|
| α-CD | β-CD | γ-CD | HP-β-CD | Methyl-β-CD | DM-β-CD | |
| Number of glucopyranose units | 6 | 7 | 8 | 7 | 7 | 7 |
| Molecular weight (Da) | 972 | 1135 | 1297 | 1541 | 1303 | 1331 |
| Solubility in water (g/100 mL) at 25 °C | 14.5 | 1.85 | 23.2 | >60 | >50 | no data available |
| Internal diameter (nm) | 0.47–0.53 | 0.60–0.65 | 0.75–0.83 | no data available | no data available | no data available |
| External diameter (nm) | 1.46 | 1.54 | 1.75 | no data available | no data available | no data available |
| Toxicological properties | no toxic effects | nephrotoxicity | no toxic effects | low hemolytic effect | cholesterol depleting property | cholesterol depleting property |
| Reference | [ | [ | [ | [ | [ | [ |
Methods of preparation for cyclodextrin inclusion complexes with triterpenic compounds.
| Triterpenic Compund | Cyclodextrin Type | Method of Preparation | State of Aggregation of the Inclusion Complex | Solvent Composition | References |
|---|---|---|---|---|---|
| Bet | γ-CD | Kneading | liquid | EtOH:water (1:1 | [ |
| BA | γ-CD | Kneading | liquid | EtOH:water (1:1 | [ |
| BA | octakis-[6-deoxy-6-(2-sulfanyl ethanesulfonic acid)]- | Kneading | liquid | EtOH:water (1:1 | [ |
| BA | β-CD | Co-precipitation | liquid | β-CD in deionized water and BA in MeOH | [ |
| OA | α-CD, β-CD | Kneading | liquid | water | [ |
| OA | amino-appended β-CDs | Slurry-complexation | liquid | water | [ |
| MA | α-CD, β-CD | Kneading | liquid | water | [ |
| UA | HP-β-CD, HP-γ-CD | Kneading | liquid | EtOH:water (1:1 | [ |
| OA | HP-β-CD, HP-γ-CD | Kneading | liquid | EtOH:water (1:1 | [ |
| Lupeol | β-CD | Spray-drying | liquid | EtOH:water (1:2 | [ |
| α,β-amyrin | β-CD, HP-β-CD | Physical mixing | solid | - | [ |
| Kneading | liquid | water and acetone | |||
| Koetjapic acid | HP-β-CD (1:2, 1:4, 1:6) | Kneading | liquid | water | [ |
| ilexgenin A | β-CD polymer | Slurry-complexation | liquid | water | [ |
Methods of preparation of cyclodextrin inclusion complexes with plant extracts containing triterpenic compounds.
| Plant Species | Triterpenes in the Extract | Cyclodextrin Type | Method of Complex Formulation | Solvent Composition | Observations | References |
|---|---|---|---|---|---|---|
| Viscum album | OA and BA | HP-β-CD | Physical mixing | - | [ | |
| Viscum album | OA and BA | HP-β-CD | Physical mixing | - | [ | |
| Centella asiatica | asiatic acid, madecassic acid, asiaticoside, | HP-β-CD | Kneading | water | [ | |
| Momordica Charantia | momordico-side K and momordico-side L | β-CD | Kneading | Juice of Momordica Charantia | [ | |
| Boswellia serrata | Boswellic acids | HP-β-CD | Kneading | EtOH:water (1:1 | [ | |
| Co-precipitation | Boswellia extract in EtOH and HP-β-CD in EtOH:water (1:1 | |||||
| Solvent evaporation | Boswellia extract in EtOH and HP-β-CD in EtOH:water (1:1 | Stirring 500 rpm for 24 h at room temperature |
Figure 3An overview of the methods used to characterize inclusion complexes in solid and liquid state (differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), hot-stage microscopy (HSM), single-crystal X-ray diffraction (SCXRD), powder X-ray diffraction (PXRD), Fourier-transform infrared (FT-IR) spectroscopy, attenuated total reflectance (ATR)-FTIR spectroscopy, nuclear magnetic resonance (NMR) and electron spin resonance (ESR)).
Kc values of inclusion complexes between HP-γ-CD and Bet derivatives.
| Triterpenic Compounds | Cyclodextrin Type | log (Kc), 25 °C | Reference |
|---|---|---|---|
| Triterpenes | |||
| Bet | HP-γ-CD | 3.82 ± 0.12 | [ |
| Triterpenoids | |||
| DPhB | HP-γ-CD | 7.23 ± 0.03 | [ |
| DScB | 7.13 ± 0.10 | ||
| DSB | 6.70 ± 0.05 | [ | |
| ASB | 7.03 ± 0.10 |
Figure 4Chemical structure of β-CD derivatives: “n” denominates the glucopyranose ring/rings where the indicated functional groups are grafted.
Figure 5An overview of the applications of CD–triterpenic compounds’ inclusion complexes and conjugates in the pharmaceutical field.
In vitro activity of triterpene:cyclodextrin inclusion complexes against cancer cell lines.
| Cyclodextrin Type | Type of Formulation | Cell Line Type | In Vitro | In Vitro Antiproliferative Results for Extracts/Triterpenic Compounds | In Vitro | Time of Incubation | References | |
|---|---|---|---|---|---|---|---|---|
| Plant Extracts | ||||||||
| A Viscum album extract containing Oleanolic acid (69.4%) and | HP-β-CD | complex | Murine melanoma | B16.F10 | 20 h | [ | ||
| Acute Lymphoblastic Leukemia | NALM-6 | Inhibition ≈ 40% | Inhibition ≈ 80% | 24 h | [ | |||
| Leukemia | U937 | Inhibition ≈ 20% | Inhibition ≈ 42% | 18 h | [ | |||
| HL-60 | Inhibition ≈ 32% | Inhibition ≈ 90% | ||||||
| Ewings Sarcoma | TC-71 | Inhibition ≈ 78% | Inhibition ≈ 80% | 24 h | [ | |||
| MHH-ES-1 | Inhibition ≈ 45% | Inhibition ≈ 50% | ||||||
| Triterpenes | ||||||||
| BA | HP-β-CD | complex | Human breast cancer | MCF-7 | 24 h | [ | ||
| octakis-[6-deoxy-6-(2-sulfanyl ethanesulfonic acid)] | Murine melanoma | metastatic B164A5 | Inhibition ≈ 42.1% | Inhibition ≈ 57.7% | 72 h | [ | ||
| non-metastatic B164A5 | Inhibition ≈ 38.2% | Inhibition ≈ 49.7% | 72 h | |||||
| UA | HP-β-CD (1:2) | complex | Melanoma | A375 | 48 h | [ | ||
| Murine melanoma | B16 4A5 | |||||||
| Melanoma | SK-Mel 2 | - | ||||||
| HP-γ-CD (1:2) | A375 | |||||||
| Murine melanoma | B16 4A5 | |||||||
| Melanoma | SK-Mel 2 | |||||||
| OA | HP-β-CD (1:2) | complex | A375 | Inhibition ≈ 50% | - | 4 h | [ | |
| Murine melanoma | B16 4A5 | Inhibition ≈ 20.7% | Inhibition ≈ 48.7% | |||||
| Melanoma | SK-Mel 2 | Inhibition ≈ 5% | - | |||||
| HP-γ-CD (1:2) | A375 | Inhibition ≈ 50% | - | |||||
| Murine melanoma | B16 4A5 | Inhibition ≈ 20.7% | Inhibition ≈ 45.7% | |||||
| Melanoma | SK-Mel 2 | Inhibition ≈ 5% | - | |||||
| OA | conjugate | Hepatocellular Carcinoma | HepG2 | 4 h | [ | |||
| Adenocarcinoma | HT29 | |||||||
| HCT116 | ||||||||
| Hepatocellular Carcinoma | HepG2 | |||||||
| Adenocarcinoma | HT29 | |||||||
| HCT116 | ||||||||
| Hepatocellular Carcinoma | HepG2 | |||||||
| Adenocarcinoma | HT29 | |||||||
| HCT116 | ||||||||
| Hepatocellular Carcinoma | HepG2 | |||||||
| Adenocarcinoma | HT29 | |||||||
| HCT116 | ||||||||
| Triterpenic saponins | ||||||||
| GA | β-CD | Complex, coupled with functionalized quantum dots | Hepatocellular Carcinoma | HepG2 | 48 h | [ | ||
| Cervical Cancer | HeLa | |||||||
| Urinary bladder carcinoma | ECV-304 | |||||||
| Saikosaponin-d | HP-β-CD (1:1) | complex | Squamous Cell Carcinoma | HSC-1 | Inhibition ≈ 45% | Inhibition ≈ 50% | 8 h | [ |
| Inhibition ≈ 65% | Inhibition ≈ 75% | 24 h | ||||||
| HP-β-CD (1:5) | Inhibition ≈ 45% | Inhibition ≈ 40% | 8 h | |||||
| Inhibition ≈ 65% | Inhibition ≈ 60% | 24 h | ||||||
| HP-β-CD (1:10) | Inhibition ≈ 45% | Inhibition ≈ 60% | 8 h | |||||
| Inhibition ≈ 65% | Inhibition ≈ 75% | 24 h | ||||||
In vivo anticancer activity of triterpene:cyclodextrin inclusion complexes.
| Plant Extract/ | Cyclodextrin Type | Animal Model | Tumor Type | Tumor Cell Lines Injected | The Concentration of the Complex | Conclusion/ | References |
|---|---|---|---|---|---|---|---|
| A Viscum album extract containing OA (69.4%) and BA (6.9%) | HP-β-CD | CB17/Icr-Prkdcscid/IcrCrl mice | Leukemia | NALM-6 | 40 mg/kg | non-significant | [ |
| Female NOD/SCID/IL2rg mice | Leukemia | HL-60 | 20/40/60/mg/kg | Reduced the tumor weight | [ | ||
| female NOD/SCID IL2rγ null mice | Ewings Sarcoma | TC-71 | 40/60/ | Induced apoptosis and reduced the tumor dimension | [ | ||
| female NMRI-nu/nu mice | |||||||
| male C57BL/6 mice | Murine melanoma | B16.F10 | Reduced tumor dimension | [ | |||
| BA | octakis-[6-deoxy-6-(2-sulfanyl ethanesulfonic acid)]- | 8-week-old C57BL/6J female mice | Murine melanoma | B164A5 | 100 mg/kg | Reduced tumor dimension and weight | [ |